Free Trial
→ Here’s Why Trump Won’t End The Iran War (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:ACRS

Aclaris Therapeutics Q3 2026 Earnings Date & Estimates

Aclaris Therapeutics logo
$3.38 -0.09 (-2.59%)
Closing price 04:00 PM Eastern
Extended Trading
$3.46 +0.08 (+2.22%)
As of 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aclaris Therapeutics is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for November 6, 2026 at 12:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
12:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Aclaris Therapeutics in Q3 2026

Aclaris Therapeutics is expected to post earnings of -$0.16 per share on revenue of $1.30 million. In the same quarter a year earlier Aclaris Therapeutics reported -$0.12 per share on revenue of $3.30 million. Aclaris Therapeutics last reported on August 6, 2026, posting -$0.15 per share and beating the -$0.16 consensus estimate. Aclaris Therapeutics has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.16
Expected Revenue
$1.30 million
Prior-Year EPS
-$0.12
Prior-Year Revenue
$3.30 million
Expected Revenue Growth
-60.7%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.15 (Beat by +$0.01)
Last Quarter Revenue
$1.63 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Aclaris Therapeutics Q3 2026 Earnings FAQ

Aclaris Therapeutics (NASDAQ:ACRS) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Aclaris Therapeutics' Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Aclaris Therapeutics to post earnings of -$0.16 per share for Q3 2026.

The consensus revenue estimate for Aclaris Therapeutics is $1.30 million for Q3 2026.

Aclaris Therapeutics Earnings Headlines

Head to Head Analysis: Aclaris Therapeutics (NASDAQ:ACRS) & Gilead Sciences (NASDAQ:GILD)
October 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31106009
Analysts Have Conflicting Sentiments on These Healthcare Companies: Aclaris Therapeutics (ACRS), Globus Medical (GMED) and Johnson & Johnson (JNJ)
October 8, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/JNJ-N/pressreleases/5065866/analysts-have-conflicting-sentiments-on-these-healthcare-companies-aclaris-therapeutics-acrs-globus-medical-gmed-and-johnson-johnson-jnj/
A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the eye-popping yields are fueling a boom among everyday investors. Three years ago, barely a dozen of these funds existed - today there are more than 100, holding over $140 billion. These funds trade on the NYSE and NASDAQ and are built to generate monthly income. Some investors are targeting $5,000 a month with roughly one-tenth of the nest egg Wall Street says you need.tc pixel
October 14 at 1:00 AM  |  Investors Alley (Ad)
Aclaris Therapeutics (NASDAQ:ACRS) Stock Falls 6.5% - What's Next?
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31088016
Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Lowered by Wall Street Zen
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31081154
Craig-Hallum Sticks to Their Buy Rating for Aclaris Therapeutics (ACRS)
September 19, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ACRS/pressreleases/3720154/craig-hallum-sticks-to-their-buy-rating-for-aclaris-therapeutics-acrs/
See More Aclaris Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aclaris Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aclaris Therapeutics and other key companies, straight to your email.

About Aclaris Therapeutics

Aclaris Therapeutics (NASDAQ:ACRS) is a clinical-stage biopharmaceutical company focused on developing therapies for immune-mediated diseases. The company’s research programs have centered on small-molecule treatments designed to address inflammatory and autoimmune conditions, including dermatologic and rheumatologic diseases.

Aclaris’ lead investigational program is zunsemetinib (ATI-450), an oral mitogen-activated protein kinase-activated protein kinase 2 (MK2) inhibitor being evaluated for potential use in inflammatory conditions such as rheumatoid arthritis and psoriasis. The company has also advanced other investigational immune-modulating programs, including therapies targeting Janus kinase (JAK) and related signaling pathways.

Historically, Aclaris developed Klisyri (tirbanibulin) ointment for the topical treatment of actinic keratosis, a precancerous skin condition. The company has conducted clinical development and commercial activities primarily in the United States, while pursuing potential partnerships and licensing arrangements for selected programs. Aclaris is headquartered in Wayne, Pennsylvania.

View Aclaris Therapeutics Profile
Earnings Tools